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Overexpression of myeloid differentiation protein 88
in mice induces mild cardiac dysfunction, but no deﬁcit
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Abstract
Cardiac remodeling involves changes in heart shape, size, structure, and function after injury to the myocardium. The proinﬂammatory
adaptor protein myeloid differentiation protein 88 (MyD88) contributes to cardiac remodeling. To investigate whether excessive MyD88
levels initiate spontaneous cardiac remodeling at the whole-organism level, we generated a transgenic MyD88 mouse model with a
cardiac-speciﬁc promoter. MyD88 mice (male, 20–30 g, n=B80) were born at the expected Mendelian ratio and demonstrated similar
morphology of the heart and cardiomyocytes with that of wild-type controls. Although heart weight was unaffected, cardiac contractility
of MyD88 hearts was mildly reduced, as shown by echocardiographic examination, compared with wild-type controls. Moreover, the
cardiac dysfunction phenotype was associated with elevation of ANF and BNP expression. Collectively, our data provide novel
evidence of the critical role of balanced MyD88 signaling in maintaining physiological function in the adult heart.
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Introduction
Cardiac remodeling refers to changes in size, shape,
structure, and function of the heart after injury to the
myocardium (1). This injury may be due to myocarditis (2),
acute myocardial infarction (3), chronic hypertension (4),
and congenital heart diseases (5,6). During cardiac
remodeling, a series of histopathological and structural
changes occur, ﬁnally resulting in reduced stroke volume
and decreased contractile function. There are multiple
mechanisms underlying cardiac remodeling, one of which
is mediated by inﬂammatory signaling molecules (7–9).
Toll-like receptors (TLRs) are pattern recognition receptors that recognize exogenous pathogen-associated molecular patterns to activate the host innate immune defense
(10). In addition to the primary role of TLRs in response to
microbial infections, TLRs can also recognize endogenous
ligands and mediate cardiac remodeling (7–9). TLRs use
ﬁve signaling adaptors to mediate receptor activation to
downstream signal transduction (11). Importantly, all TLRs,
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except for TLR3, signal through myeloid differentiation factor
88 (MyD88) for activation of nuclear factor-kB, leading to the
production of inﬂammatory mediators (12).
Although MyD88 was originally identiﬁed as a myeloiddifferentiation marker (13), MyD88 is typically known to
play an essential role in the innate immune response (14).
Generation of MyD88-deﬁcient mice has revealed new
and important insights into the function of MyD88 in
cardiac remodeling of several cardiomyopathy diseases.
MyD88-knockout mice are protected from experimental
autoimmune myocarditis (15), Coxsackievirus B3-induced
myocarditis (16), and endotoxin-induced cardiomyopathy
(17–19). Speciﬁcally, Feng et al. (19) demonstrated that
cardiac MyD88 mainly contributes to myocardial inducible
nitric oxide synthase induction. Interestingly, our previous
studies using cardiac-speciﬁc dominant negative MyD88
(dnMyD88) transgenic mice demonstrated that uncontrolled MyD88 signaling triggers dilated cardiomyopathy
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and spontaneous heart failure (20). The above-mentioned
results indicate the comprehensive role of MyD88 in
maintenance of heart function. However, whether enforced
expression of MyD88 initiates spontaneous cardiac remodeling at the whole-organism level remains unclear.
To determine whether excessive MyD88 induces in vivo
cardiac remodeling at baseline, we targeted MyD88 expression in the myocardium of transgenic mice via an a-myosin
heavy chain (a-MHC) promoter. Each transgenic line was
viable and demonstrated a signiﬁcant elevation in basal
MyD88 expression. Our data suggested that overexpression
of MyD88 did not trigger obvious abnormality in heart
morphology, but promoted mild cardiac dysfunction at
baseline, with an elevation in heart failure marker expression.

Material and Methods
Generation of transgenic mice
Mice (male, 20–30g, n=B80) were maintained in an
Association for Assessment and Accreditation of Laboratory Animal Care International-credited speciﬁc pathogenfree animal facility of the Model Animal Research Center
(MARC) of Nanjing University. All animal protocols were
approved based on the local ethics legislation for animal
experimentation. Animal welfare and experimental procedures were conducted with the approval of the Institutional
Animal Care and Use Committee of MARC.
The transgenic construct contains the a-MHC promoter (21), Flag-tagged MyD88 cDNA, and a human growth
hormone poly-adenylation signal. MyD88 cDNA was ampliﬁed and ligated into the SalI and HindIII sites of the murine
a-MHC promoter expression vector. The encoded MyD88
protein has the Flag tag at the N-terminal. Transgenic mice
were generated through pronuclear microinjection of one-cell
embryos from the C57BL/6J  CBA F1 hybrid (The Jackson
Laboratory, USA). Positive founders were identiﬁed by
PCR and backcrossed to wild-type (WT) C57BL/6J mice.
Genotyping was performed by PCR analyses with the primer
sets 5-TTTATCTGCTACTGCCCCAACG-3 (located in exon
3) and 5-CTGGGAAAGTCCTTCTTCATCG-3 (located in
exon 5), which were designed to amplify a 711-bp fragment
from endogenous MyD88 and a 308-bp fragment from the
transgenic MyD88 construct.
Cytoplasmic protein extraction and western blotting
Myocardial tissue proteins were extracted using
10 mmol/L HEPES, pH 7.9, 10 mmol/L KCl, 0.1 mmol/L
EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, and protease
inhibitors. Protein concentrations were determined by the
bicinchoninic acid assay (Pierce Chemical Co., USA).
Equal amounts of protein samples were subjected to
western blotting as described previously (22,23). Immunoreactivity was revealed with an enhanced chemiluminescent substrate for peroxidase (SuperSignal West Pico
substrate, Pierce Chemical Co., USA). Flag antibody was
purchased from Sigma (USA).
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Histological examination
A single 3-mm slice of each heart was taken at a similar
anatomical location. Sliced tissues were then immersionﬁxed in 4% buffered paraformaldehyde and embedded in
parafﬁn (Sigma-Aldrich, USA) for preparation of tissue
sections. Serial 5-mm heart sections from each group were
analyzed. Hematoxylin and eosin (H&E) staining was
subsequently performed on dewaxed sections.
Semi-quantitative RT PCR
Total RNA was extracted and reverse-transcribed to
cDNA using the PrimeScript2 RT-PCR Kit (Takara, Japan).
Semi-quantitative RT PCR was performed to examine mRNA
expression of atrial natriuretic factor (ANF) (5-CGGTGTCCA
ACACAGATCTGAT-3 and 5-GGCTCCAATCCTGTCAATCC
TAC-3) and brain natriuretic peptide (BNP) (5-CGAGACA
AGGGAGAACACG-3 and 5-CCAAAGCAGCTTGAGATA
TGT-3). Ampliﬁcation of tubulin (5-TCCATCCACGTCGGC
CAGGCT-3 and 5-GTAGGGCTCAACCACAGCAGT-3)
served as an input control of cDNA templates.
Echocardiography
Mice were lightly anesthetized and then their heart
function was analyzed using a GE Vingmed Vivid
7 ultrasound scanner (GE Healthcare, USA) with the GE
i13L epicardial probe (linear phased array). Echocardiographic measurements were performed in M-mode by an
echocardiographer who was blinded to the experimental
design as described previously (20).
Statistical analysis
Statistical analysis was performed with the Graphpad
Prism 5 software (Graphpad, USA). The P values were
based on the two-tailed Student’s t-test and data are
reported as means±SE. The null hypothesis was rejected
for P values less than 0.05 with the two-tailed test.

Results
Generation and characterization of MyD88 transgenic
mice
In this study, we targeted Flag-tagged MyD88 expression to the myocardium in transgenic mice using the
a-MHC promoter (Figure 1A). The a-MHC promoter
directs high-level gene expression speciﬁcally in the
myocardium after birth (24). The encoded MyD88 protein
had the Flag tag at the N-terminal. Four independent
transgenic founder lines were established. MyD88 mice
were born at the expected Mendelian ratio. Among these
independent lines, lines B and D were selected for further
analysis based on comparable transgene expression
levels, viability, and germline transmission. WT littermates
were used as controls in all experiments. PCR of genomic
DNA from mouse tails was performed to verify the expected genotypes (Figure 1B). A high level of transgene
expression was observed in the MyD88 transgenic (TG)
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Figure 1. Generation of cardiac-speciﬁc transgenic (TG) mice
overexpressing MyD88. A, Construction map of MyD88 TG mice.
MHC: myosin heavy chain; MyD88: myeloid differentiation factor 88;
hGH-pA: human growth hormone poly A signal; WT: wild-type. B,
PCR of genomic DNA from mouse tails was performed for
genotyping. A 711-bp fragment from the genomic MyD88 allele and
a 308-bp fragment from the transgenic Flag-MyD88 allele was PCRampliﬁed with the genotyping primers. C, Tissue-speciﬁc expression
of the transgene in MyD88 TG mice was performed with anti-Flag
antibody. H: heart; SM: skeletal muscle; Li: liver; Sp: spleen; Lu: lungs;
Ki: kidney; Br: brain.

heart of lines B and D (Figure 1C). Weak MyD88 transgene expression was also detected in the spleen of line B
and in the kidneys of line D (Figure 1C).
MyD88 TG mice did not display any abnormality in
heart morphology
Disease progression of human heart failure causes a
marked increase in cardiac chamber volume (25). WT and
MyD88 TG mice were euthanized at 5 months of age for
analysis of cardiac anatomy and histology. As shown in
Figure 2A, MyD88 TG hearts showed similar morphology
to WT hearts. We performed further H&E staining on serial
tissue sections (Figure 2B). No abnormalities in cell size
and morphology were observed in left ventricles of MyD88
TG hearts.
We then used rigorous and unbiased methods to
check the relative heart weight (Figure 3A). By 5 months
of age, the heart weight to body weight ratio (HW/BW) and
heart weight to tibia length ratio (HW/TL) of MyD88 TG
mice remained unchanged in lines B and D compared with
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Figure 2. Histological analysis of MyD88 transgenic (TG) hearts.
A, Gross appearance of the isolated wild-type (WT) and TG heart.
B, Microscopic view of H&E-stained left ventricular sections from
MyD88 TG and WT mice. Scale bar: 2 mm.

those of age-matched WT mice. We used the liver weight
to body weight ratio (LW/BW) and liver weight to tibia
length ratio (LW/TL) as internal controls.
To clearly characterize physiological cardiac parameters of MyD88 TG mice, M-mode echocardiography
was performed at 5 months of age (Figure 3B). Consistent
with the heart weight data, no differences in left ventricular
end-diastolic dimension (LVEDD), left ventricular endstolic dimension (LVESD), interventricular septal thickness
in diastole, and posterior wall thickness in diastole were
observed in MyD88 TG mice, suggesting normal anatomy
of MyD88 hearts.
MyD88 transgenic mice developed reduced cardiac
contractility at baseline
To directly determine cardiac contractility of MyD88
TG mice, echocardiography was performed on mice
at the age of 5 months (Figure 4A). Fractional shortening (FS) is a popular echocardiographic index for left
ventricular systolic contractility. As shown in Figure 4B,
FS was reduced in MyD88 TG mice compared with WT
mice (78.4%, Po0.05 for line B; 76.2%, Po0.05 for line
D). Similarly, the ejection fraction, another index for
left ventricular contractility, was also downregulated
accordingly (88.0%, Po0.05 for line B; 85.2%, Po0.01
for line D).
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Figure 3. MyD88 transgenic (TG) mice did not
show an increased heart size. Data are reported
as means ± SE. A, Relative heart weights (HW/
BW and HW/TL) of wild-type (WT) and TG mice
at 5 months of age. HW: heart weight (mg); BW:
body weight (g); TL: tibia length (mm); LW: liver
weight (g) (n=3–6). The heart and liver were
removed, weighed, and normalized to body
weight or tibia length. B, Echocardiographic
analysis of WT and TG hearts at 5 months of
age (n=5–11). LVEDD: left ventricular end-diastolic
dimension; LVESD: left ventricular end-systolic
dimension; IVSTD: interventricular septal thickness in diastole; PWTD: posterior wall thickness in
diastole; *Po0.05 (two-tailed Student’s t-test).

Heart failure is closely associated with re-expression
of fetal genes or upregulation of cardiac proteins, such as
ANF and BNP (26). To more rigorously characterize the
phenotype of MyD88 transgenic mice, mRNA expression
of heart failure markers was performed. Consistent with
the cardiac dysfunction phenotype, mRNA levels of ANF
and BNP were elevated in MyD88 TG myocardium by 2
and 5 months of age compared with WT mice, which
indicated that the molecular program for heart failure had
been initiated (Figure 4C).

Discussion
In this study, we analyzed a mouse strain with cardiac
overexpression of MyD88 protein. We found that balanced
MyD88 signaling maintained normal heart function. MyD88
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TG mice developed mild cardiac dysfunction, without obvious
abnormalities in cardiac morphology. This ﬁnding suggests a
potential protective effect on the heart from excessive MyD88
expression.
Our study showed that excessive MyD88 did not
trigger serious cardiac remodeling at the whole-organism
level. In line with our observations, a previous study
showed that transiently transfected MyD88 accumulates
in granules and in larger, condensed structures throughout
the nucleus and cytoplasm of HeLa cells (27). Consistent
with these ﬁndings, Iliev et al. (28) reported that the
ectopically expressed transgenic salmon MyD88 homolog
(SsMyD88) accumulates in aggresomes, indicating that
MyD88 might represent a defense mechanism against
the potentially harmful effects of excessive MyD88 signaling. Therefore, unsurprisingly, excessive MyD88 did not
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Figure 4. MyD88 transgenic (TG) mice showed reduced cardiac contractility and elevated heart failure marker expression.
A, Representative M-mode echocardiographic views of wild-type (WT) and TG hearts at 5 months (M) of age. Scale bar, 20 mm.
B, Statistical analysis of echocardiographic parameters of WT and TG mice (n=5–11). FS%: fractional shortening, FS% = (LVEDD
LVESD)/LVEDD  100; EF%: ejection fraction, EF% = (LVEDD3 LVESD3)/LVEDD3  100. *Po0.05, **Po0.01 compared to WT (twotailed Student’s t-test). C, Measurement of atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) mRNA levels in WT and TG
hearts at 2 and 5 months of age.

trigger spontaneous extensive cardiac remodeling in our
model.
A potential concern related to our study is that overexpression of a protein in the heart might induce a nonspeciﬁc biological effect, resulting in cardiac dysfunction
(29). However, more than one line of MyD88 transgenic
mice demonstrated a similar cardiac dysfunction phenotype. This ﬁnding indicated that the observed phenotype
was not related to overexpression-induced toxicity.
In summary, we generated a heart-speciﬁc MyD88
overexpression model to evaluate the potential harmful
effect of excessive cardiac MyD88 signaling on pathogenesis of baseline cardiac remodeling. Our study shows that

overexpression of MyD88 induced mild cardiac dysfunction without obvious abnormalities in heart morphology,
suggesting a comprehensive role for MyD88 in cardiac
remodeling responses.
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